Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients.
Phase 2
Recruiting
- Conditions
- Intensive Care UnitCardiac SurgeryHigh Risk PatientsCardiopulmonary BypassValve Surgeries
- Interventions
- Drug: Long-chain n-3 fatty acidsDrug: Intravenous 0.9% Sodium Chloride
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- GCP-Service International West GmbH
- Target Recruit Count
- 120
- Registration Number
- NCT06279793
- Locations
- 🇩🇪
University Hospital Goettingen, Göttingen, Germany
🇩🇪University Hospital Muenster, Muenster, Germany
🇩🇪Charité Universitätsmedizin Berlin, Berlin, Germany
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Phase 2
Not yet recruiting
- Conditions
- Low Risk Myelodysplastic Syndromes
- Interventions
- Drug: RVU120 (SEL120)
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- GCP-Service International West GmbH
- Target Recruit Count
- 41
- Registration Number
- NCT06243458
- Locations
- 🇫🇷
CHU Grenoble Alpes - Hôpital Michallon, Grenoble, France
🇫🇷CHU de Nice - Hôpital l'Archet 1, Nice, France
🇫🇷Hôpital Saint-Louis, Service d'Hématologie Séniors, Paris, France
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Phase 2
Active, not recruiting
- Conditions
- Myelodysplastic SyndromesAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- GCP-Service International West GmbH
- Target Recruit Count
- 46
- Registration Number
- NCT05583552
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺Royal Brisbane and Women's Hospitals, Brisbane, Australia
🇦🇺Linear Clinical Research, Nedlands, Australia
© Copyright 2025. All Rights Reserved by MedPath